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mallpox Vaccination and
yopericarditis: A Clinical Review
imitri C. Cassimatis, MD,* J. Edwin Atwood, MD, FACC,* Renata M. Engler, MD,*
eter E. Linz, MD, FACC,† John D. Grabenstein, PHD,‡ Marina N. Vernalis, DO, FACC*
ashington, DC; San Diego, California; and Falls Church, Virginia
Smallpox is a devastating viral illness that was eradicated after an aggressive, widespread
vaccination campaign. Routine U.S. childhood vaccinations ended in 1972, and routine
military vaccinations ended in 1990. Recently, the threat of bioterrorist use of smallpox has
revived the need for vaccination. Over 450,000 U.S. military personnel received the
vaccination between December 2002 and June 2003, with rates of non-cardiac complications
at or below historical levels. The rate of cardiac complications, however, has been higher than
expected, with two confirmed cases and over 50 probable cases of myopericarditis after
vaccination reported to the Department of Defense Smallpox Vaccination Program. The
practicing physician should use the history and physical, electrocardiogram, and cardiac
biomarkers in the initial evaluation of a post-vaccination patient with chest pain. Echocar-
diogram, cardiac catheterization, magnetic resonance imaging, nuclear imaging, and cardiac
biopsy may be of use in further workup. Treatment is with non-steroidal anti-inflammatory
agents, four to six weeks of limited exertion, and conventional heart failure treatment as
necessary. Immune suppressant therapy with steroids may be uniquely beneficial in myoperi-
carditis related to smallpox vaccination, compared with other types of myopericarditis. If a
widespread vaccination program is undertaken in the future, many more cases of post-
vaccinial myopericarditis could be seen. Practicing physicians should be aware that smallpox
vaccine-associated myopericarditis is a real entity, and symptoms after vaccination should be
appropriately evaluated, treated if necessary, and reported to the Vaccine Adverse Events
Reporting System. (J Am Coll Cardiol 2004;43:1503–10) © 2004 by the American College
of Cardiology FoundationH
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fmallpox is a devastating viral illness that was eradicated
fter an aggressive widespread vaccination campaign. Rou-
ine U.S. childhood vaccinations ended in 1972, and routine
ilitary vaccinations ended in 1990. Recently, the threat of
ioterrorist use of smallpox has revived the need for vacci-
ation. Over 450,000 U.S. military personnel received the
accination between December 2002 and June 2003, with
ates of non-cardiac complications at or below historical
evels (1). The rate of cardiac complications, however, has
een higher than expected, with two confirmed cases and
ver 50 probable cases of myocarditis after vaccination
eported to the Department of Defense (DoD) Smallpox
accination Program. Halsell et al. (2), in an analysis of the
rst 230,734 primary vaccinees, recently reported a rate of 1
ase of myopericarditis per 12,819 primary vaccinees. As
ilitary and civilian vaccination programs continue and
ore people are vaccinated, it will be important for prac-
icing cardiologists and primary-care physicians to be aware
f the potential for cardiac complication.
From the *Walter Reed Army Medical Center, Washington, DC; †Naval Medical
enter San Diego, San Diego, California; and ‡Military Vaccine Agency, United
tates Army Medical Command, Falls Church, Virginia. The opinions or assertions
ontained herein are the private views of the authors and are not to be construed as
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mallpox was a highly contagious viral disease, spread by
espiratory droplet, endemic in every country in the world,
hich at times decimated populations and disfigured mil-
ions. It was described in Asia as far back as the first century
.D., and since then has been described in Europe, Africa,
nd the Americas. At one time it may have accounted for
0% of all deaths in the world (3).
Smallpox is caused by the variola virus, which enters via
he respiratory tract to infect local lymph nodes. The clinical
ourse of smallpox has been recently well described by
reman and Henderson (4). In brief, it causes a generalized
ustular rash and fever after a 7- to 17-day incubation
eriod. Death, if it occurs, is believed to be secondary to
oxemia and shock (5). Five types of smallpox infection have
een described, of varying severity (6). The most common,
ccounting for about 90% of cases, is variola major and has
mortality of about 30% in adults, and even higher in
nfants and children. A milder form of variola infection,
escribed as variola minor, rarely occurred in unvaccinated
ersons but made up approximately 25% of smallpox infec-
ions in those who had been vaccinated and was usually well
olerated. The worst types, hemorrhagic and flat, accounted
or 10% or less of cases and were almost always fatal.
reviously infected or vaccinated people could also get a
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Smallpox Vaccination and Myopericarditis May 5, 2004:1503–10ild form called variola sine eruptione, which was 1%
atal and almost never contagious.
Early attempts at vaccination to prevent smallpox used
he actual virus itself in a process called variolation. Dried
cab material from pustular wounds of mildly infected
ersons was intentionally scratched into the skin of unin-
ected persons. However, this led to approximately 1% of
accinees contracting severe systemic infections (6,7). In
796, Edward Jenner observed that a nurse caring for his
on had contracted swinepox and appeared to be immune.
e infected three other people from the swinepox lesions
nd then variolated them with smallpox with no subsequent
nfection occurring. He later demonstrated better protective
mmunity with cowpox rather than with swinepox. This
bservation led to the successful vaccination of an eight-
ear-old boy using material from a cowpox lesion. The
rocess was repeated in others and found to be safer than
ariolation. The practice of vaccination was slow to catch
n, but after considerable effort by Jenner it became a
ommon procedure in Europe and America (3,8).
Current vaccines utilize another poxvirus, vaccinia virus.
accinia, cowpox, and variola virus are all poxviruses, of
he same subfamily Chordopoxvirinae and genus orthopox-
irus (4,6). The origin of vaccinia virus is unclear, but
ecause of the ease with which it is cultivated on many
ifferent animals, it became the vaccine of choice to prevent
mallpox.
In 1959, the World Health Organization set out to
radicate smallpox from the earth. They capitalized on the
vailability of an effective vaccine, the absence of any
on-human reservoir for variola, the lack of an asymptom-
tic carrier state, and a long incubation period enabling
accination to modify the course of the illness (6). Through
n aggressive program of case detection, quarantine of the
nfected, and vaccination of contacts, the World Health
rganization was eventually successful. The eradication of
mallpox was declared in 1980 (9).
Routine childhood vaccinations in the U.S. were stopped
n 1972, and worldwide by 1982. There is now a large
opulation of never vaccinated persons who would be
usceptible to infection, and an older population with
aning immunity from their vaccinations received over 20
ears ago (6). In addition, there is a population of immu-
ocompromised individuals, from those with human immu-
Abbreviations and Acronyms
CDC  Centers for Disease Control and Prevention
CRP  C-reactive protein
DoD  Department of Defense
ECG  electrocardiogram
ESR  erythrocyte sedimentation rate
MRI  magnetic resonance imaging
NSAID  non-steroidal anti-inflammatory drug
VIG  vaccinia immune globulinodeficiency virus infection to transplant survivors, who are at significantly greater risk for mortality and largely did not
xist during the smallpox era before its eradication in 1980.
his, combined with the concern that smallpox could be
sed as a bioterrorism weapon, has renewed interest in
accination, especially in military personnel who might face
xposure during the performance of their duties and in
ealth care workers who might care for the ill.
Vaccination of military personnel resumed in December
002 in many centers across the U.S. Since that time, over
68,000 military personnel and 38,000 civilians have re-
eived the smallpox vaccine (10). The Vaccine Healthcare
enter Network, a collaborative effort between the DoD
nd the Centers for Disease Control and Prevention
CDC), developed initially at Walter Reed Army Medical
enter, has facilitated the surveillance and case manage-
ent of vaccine-associated events (Vaccine Adverse Events
eporting System) experienced by service members (1).
The DoD commitment to close surveillance of adverse
vents has identified an increased rate of pericarditis and
yocarditis in temporal association with smallpox vaccina-
ion compared with rates seen in comparable unvaccinated
opulations within the DoD in 2002. In addition, questions
ave been raised regarding other cardiac events, such as
yocardial infarctions and arrhythmias occurring after im-
unization. To date, ischemic cardiac events have not
ccurred at a frequency exceeding expected population rates
1).
ARDIAC COMPLICATIONS
F SMALLPOX VACCINATION
ardiac complications were reported in Europe during the
rst wave of vaccinations of the 1950s and 1960s. A review
f the worldwide literature reveals at least 7 fatal (11–13)
nd 59 non-fatal cases of post-vaccinial myocarditis among
dults (13–25) using autopsy, symptoms, and/or electrocar-
iogram (ECG) changes to diagnose myocarditis and/or
ericarditis. Estimates of incidence range from as high as
% to 3%, based on the number of Swedish military recruits
ith asymptomatic T-wave changes after vaccination
14,20), to 1 in 10,000, a number calculated in a 1983
innish study on the basis of 12 reported cases divided by
he number of military vaccinees in that interval (21).
ecovery was most common and within three weeks in
hose cases that received follow-up.
Of the seven fatal cases, five are from a 1953 French
eport of five fatal myocardial infarctions occurring after
mallpox vaccination (13). All had been stable before
accination, and two of the five had known coronary artery
isease. The authors concluded that those with known
oronary artery disease or over the age of 50 with risks for
ascular disease should not be vaccinated, even though they
ad not proven that their cases went beyond expected
ackground rates. The other two fatal cases reported in
urope both showed lymphocytic infiltration of the heart onutopsy (11,12).
l
p
a
m
R
n
v
i
d
d
f
o
t
v
s
n
e
v
v
a
s
p
m
p
a
e
o
n
s
n
c
l
s
2
p
d
e
e
a
D
H
b
i
t
n
T
p
c
F
i
w
v
U
k
a
a
t
b
t
T
S
P
C
S
P
C
*
; LV
1505JACC Vol. 43, No. 9, 2004 Cassimatis et al.
May 5, 2004:1503–10 Smallpox Vaccination and MyopericarditisIn the same time period up to 1970, the European
iterature reported at least seven non-fatal pediatric cases of
ost-vaccinial myopericarditis (26–29) and two fatal pedi-
tric cases (30,31), both with inflammatory infiltrate (but no
ention of eosinophils) of the myocardium on autopsy.
eview of the Australian literature produced reports of 11
on-fatal (32–34) and 1 fatal (35) adult cases of post-
accinial myopericarditis, the last with a mixed cardiac
nfiltrate on autopsy.
Conversely, cardiac complications were rarely described
uring that time period in the U.S. The American literature
iscusses only two non-fatal adult cases (36,37) and two
atal adult cases (38,39). Multiple reports exist discussing
ther complications, but none were cardiac (40–43). It was
hought that this was due to the use of a different strain of
accinia in the U.S., the New York City Board of Health
train (Dryvax, Wyeth Laboratories, Marietta, Pennsylva-
ia) than was used in Europe or Australia. Given the current
xperiences using the New York City Board of Health
accine strain in the last year, we must now question the
alidity of this assumption and wonder if the difference was
ctually due to variations in monitoring and reporting.
With the benefit of a more structured reporting system
et up by the DoD, we have extensive data on the 468,000
ersonnel who have been vaccinated. Personnel have been
onitored for evidence of multiple adverse events, including
ericarditis and myocarditis. For purposes of data collection
nd reporting, the two have been combined into a single
ntity “myopericarditis” indicating signs and symptoms of
ne or both. As the program evolved and an increasing
umber of cases were reviewed, the DoD and CDC
mallpox vaccination working groups developed case defi-
able 1. Case Definition of Myo/Pericarditis for Use in Smallpox
Level of Suspicion
uspected myocarditis 1) Symptoms (dyspnea, palpitations, or chest
2) ECG abnormalities beyond normal variants
tachycardia, ventricular tachycardia, atrioven
depressed LV function of uncertain age by
3) Absence of evidence of any other likely cau
robable myocarditis 1) Meets criteria for suspected myocarditis
2) In addition, meets one of the following: ele
I), OR new onset of depressed LV function
gadolinium, gallium-67 scanning, anti-myos
onfirmed myocarditis 1) Histopathologic evidence of myocarditis by
uspected pericarditis 1) Typical chest pain (made worse by supine p
2) No evidence for alternative cause of such p
robable pericarditis 1) Meets criteria for suspected pericarditis
2) Has one or more of the following: pericard
PR-segment depressions not previously doc
onfirmed pericarditis 1) Histopathologic evidence of pericardial infl
Summary, adapted from the CDC website, MMWR weekly, May 30, 2003.
CDC  Centers for Disease Control and Prevention; ECG  electrocardiogramitions for epidemiologic surveillance purposes of myoperi- oarditis (either pericarditis, myocarditis, or both) with the
evel of evidence to support the diagnosis being ranked as
uspected, probable, or confirmed (Table 1). As of June 15,
003, DoD has identified over 50 cases of suspected,
robable, or confirmed myopericarditis occurring within 30
ays of vaccination in these personnel, based upon clinical
valuation of symptoms, ECG, cardiac enzyme assays,
chocardiography, and the exclusion of ischemic coronary
rtery disease.
IAGNOSIS AND REPORTING
istory and symptoms. Patients with myopericarditis may
e asymptomatic or may report a range of symptoms,
ncluding chest pain, fatigue, shortness of breath, palpita-
ions, decreased exercise tolerance, orthopnea, paroxysmal
octurnal dyspnea, increasing edema, and lightheadedness.
he chest pain is classically a burning or a pressure that is
leuritic and may be relieved by sitting forward. It is often
onstant and without any relationship to exertion. As the
innish studies have shown, asymptomatic ECG abnormal-
ties (non-specific ST-T abnormalities that return to normal
ithin 6 months) occur in up to 2% to 3% of smallpox
accinees, the exact meaning of which is uncertain (14,20).
nfortunately, no studies to date have used cardiac biomar-
ers in a similar population to investigate these ECG
bnormalities. Thus, the clinical significance of asymptom-
tic ECG changes post-vaccination remains unclear.
Finding a causal relationship between smallpox vaccina-
ion and myopericarditis relies heavily on a temporal link
etween the timing of vaccination and the onset of symp-
oms and/or ECG changes. Because tests for viremia are
verse Events Monitoring*
escription of Criteria
documented previously (ST/T abnormality, paroxysmal supraventricular
ar block, frequent atrial or ventricular ectopy) OR focal or diffuse
aging study
levels of cardiac enzymes (creatine kinase-MB fraction, troponin T or
aging, OR abnormal imaging consistent with myocarditis (MRI with
tibody scanning)
myocardial biopsy or on autopsy
n, improved with leaning forward, pleuritic, constant)
b on auscultation OR ECG with diffuse ST-segment elevations or
ted OR echocardiogram revealing an abnormal pericardial effusion
tion in pericardial tissue from surgery or autopsy
 left ventricle; MRI  magnetic resonance imaging.Ad
D
pain)
, not
tricul
an im
se
vated
by im
in an
endo
ositio
ain
ial ru
umen
ammanly rarely positive (16,21,44,45), and viral antibody titers
w
t
v
m
r
d
s
E
t
c
s
i
n
S
b
a
d
C
m
(
a
d
p
d
i
m
d
d
c
m
E
f
e
n
p
d
p
d
a
b
v
c
C
s
a
s
m
c
t
i
i
n
m
t
(
t
s
m
e
t
t
i
d
t
l
t
e
a
E
f
v
d
d
m
M
i
b
e
d
h
h
d
u
w
b
a
s
l
a
c
a
I
s
S
b
s
s
c
p
h
i
r
e
m
h
s
w
G
m
c
1506 Cassimatis et al. JACC Vol. 43, No. 9, 2004
Smallpox Vaccination and Myopericarditis May 5, 2004:1503–10ould normally go up after a successful vaccination, these
wo tests are useful for ruling out rare instances of active
iral infection but not helpful in finding a cause in the
ajority of cases. Therefore, we must rely on a temporal
elationship, and accept that there may be the rare coinci-
ental case not due to smallpox vaccination but occurring
oon after it.
CG. Classically, ECG has been the primary diagnostic
ool in the diagnosis of myopericarditis. Nearly all of the
ase reports from 1980 or before rely on symptoms alone or
ymptoms with ECG changes. These changes are predom-
nantly ST- or T-wave abnormalities ranging from mild,
on-specific T-wave flattening and inversion to dramatic
T-segment elevations that evolve into T-wave inversions
ut not Q waves. The presence of ECG abnormalities in the
ppropriate clinical setting is highly suggestive, but not
iagnostic, of myopericarditis.
ardiac catheterization. It has been well shown that
yopericarditis often mimics acute myocardial infarction
13,46–48). Cardiac catheterization is primarily used in this
cute setting to distinguish ischemic from inflammatory cell
eath. Although it is not diagnostic of myopericarditis, it
lays a key role by diagnosing or excluding ischemic heart
isease. In some cases in which suspicion of myopericarditis
s high and coronary artery disease risk is low, it may be
ore appropriate to non-invasively rule out ischemic heart
isease with a stress imaging test such as a stress echocar-
iogram or a nuclear stress perfusion scan. Right heart
atheterization may be indicated in cases involving compro-
ised hemodynamic function and suspected tamponade.
ndomyocardial biopsy. Although it is the gold standard
or the diagnosis of myocarditis, biopsy is of limited utility,
specially in acute myocarditis, because of the often patchy
ature of active inflammation. In a large series of over 2,000
atients with clinically suspected myocarditis, endomyocar-
ial biopsy was positive in only 10% (49–51). Wu et al. (52)
rovide a concise review of the indications for endomyocar-
ial biopsy in the management of dilated cardiomyopathy
nd myocarditis. Given the risks of biopsy and the limited
enefit, its use should be limited to the patient with left
entricular dysfunction and symptoms not responsive to
onventional medical management.
ardiac enzymes and markers of inflammation. Earlier
tudies of post-vaccinial myopericarditis sporadically evalu-
ted non-specific cardiac enzymes. More recent studies have
hown both troponin T and I to be fairly specific for
yocarditis when used in conjunction with clinical suspi-
ion (53,54). Although they are significantly more sensitive
han creatine kinase-MB fraction in detecting myocardial
njury, both will be normal in 44% to 66% of subjects with
mmunohistologic evidence of myocarditis (53). Although a
egative troponin assay may be of limited utility, when
atched to the clinical suspicion of myocarditis, an eleva-
ion of troponin is over 90% predictive of myocarditis
53,54). Troponin T and troponin I are useful adjuncts in
he workup of potential myopericarditis, and positive values chould significantly raise suspicion of myocarditis but nor-
al values alone should not rule it out.
Markers of inflammation in the serum, namely the
rythrocyte sedimentation rate (ESR) and C-reactive pro-
ein (CRP), have not been thoroughly reviewed as diagnos-
ic tools in myopericarditis. They are general markers of
nflammation that are more sensitive than specific, as they
o not differentiate between causes of inflammation. Given
heir low cost, both ESR and CRP are fundamental
aboratory assays in working up possible myopericarditis, as
hey will help to show if a general inflammatory state is in
ffect, and in theory are likely predictive of benefit from
nti-inflammatory treatment.
chocardiogram. The echocardiogram is extremely useful
or localizing wall motion abnormalities, evaluating left
entricular function, identifying a pericardial effusion, and
emonstrating tamponade. Although not helpful in the
efinitive diagnosis of myopericarditis, the echocardiogram
ay greatly affect treatment and medical management.
agnetic resonance imaging (MRI). Although the stud-
es looking at MRI in the diagnosis of myocarditis have
een small, they are promising. When MRI images are
xamined for post-gadolinium enhancement of the myocar-
ium, almost 100% of patients show focal or diffuse en-
ancement not seen in normal control subjects. Two studies
ave shown 100% sensitivity and specificity for myocarditis
etection by MRI (55,56), and an editorial encourages its
se to detect myocarditis (57). Magnetic resonance imaging
ill initially show a focal enhancement in acute myocarditis,
ut within a week this becomes diffuse (55,58). The MRI
bnormalities may persist at least one month after onset of
ymptoms (55). Magnetic resonance imaging is a useful and
ikely underutilized tool in the diagnosis of myopericarditis
nd should be considered in any case that is not made
ompletely clear by less expensive tests and clinical history
nd presentation.
ndium-111 antimyosin antibody scintigraphy. This
tudy uses radiolabelled antibodies to cardiac myosin (Myo-
cint, Centocor) to localize areas of cardiac cell death. It has
een shown to be approximately 66% sensitive and 71%
pecific in the detection of myocarditis in patients clinically
uspected of myocarditis (59). It may be especially helpful in
onjunction with resting thallium images in working up
atients with suspected acute myocardial infarction who
ave normal cardiac catheterizations. By showing areas of
nflammation with the antimyosin antibody scan that cor-
espond to areas of normal perfusion by thallium scan, Sarda
t al. (60) showed that 78% of patients with suspected acute
yocardial infarction but normal cardiac catheterization
ad likely myocarditis. Given the limited availability of this
can and the lower sensitivity and specificity than that seen
ith MRI, cardiac MRI appears to be the study of choice.
allium-67 scan of the heart. Gallium-67 scanning
akes use of the fact that gallium-67 binds to white blood
ells and reveals areas of inflammation. In a 1984 study
omparing gallium scan to the gold standard of biopsy in
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May 5, 2004:1503–10 Smallpox Vaccination and Myopericarditisatients with dilated cardiomyopathy, gallium scanning
emonstrated 87% sensitivity and 86% specificity for myo-
arditis (61).
iremia. Historically, viremia was detected in only one
ase of fatal myopericarditis (39) by electron microscopy. In
he DoD’s case series, two cases were biopsied, neither of
hich revealed vaccinia virus by polymerase chain reaction
r viral culture. A study of Coxsackie myocarditis revealed
hat in 41 patients with myocarditis and antibodies to
oxsackie, virus was isolated from only three patients (44).
n part, this may be due to difficulty in accurately identifying
he virus, but most likely it means that most cases of
ost-viral myocarditis take place after completion of active
iral infection. This both points to an autoimmune mech-
nism, perhaps virally triggered, and it means that viral
ultures and searching for active infection may be of limited
alue in patients with myopericarditis.
Based on the above information and expert consensus, the
oD Vaccine Healthcare Center Network in collaboration
ith the Smallpox Vaccination Cardiac Working Group has
eveloped a clinical guideline algorithm to standardize the
igure 1. Adapted from the clinical guideline algorithm used by the Depa
-reactive protein; ECG electrocardiogram; ESR erythrocyte sedimen
non-steroidal anti-inflammatory drug; PA  posteroanterior; PCR valuation and follow-up of individuals presenting with iossible myopericarditis. The attached algorithm delineates
he current approach (Fig. 1).
EVIEW OF TREATMENT OPTIONS
mmunosuppressive therapy. Baldini and Bani (26) re-
orted three cases in Italy of post-vaccinial myopericarditis,
ach managed with corticosteroids, and all three recovering.
atthews and Griffiths (24) reported a 25-year-old patient
n the United Kingdom with post-vaccinial myopericarditis
nd congestive heart failure symptoms who showed dra-
atic recovery with steroid therapy (intravenous hydrocor-
isone initially and then oral prednisone). A pediatric
atient in Greece became severely ill with myocarditis and
ongestive heart failure after smallpox vaccination, and also
ad a dramatic recovery after receiving cortisone and vac-
inia immune globulin (VIG) (29). This latter case is
specially intriguing, as the two treatments VIG and ste-
oids work in nearly opposite ways: VIG neutralizes active
iral infection, whereas steroids break an autoimmune
nflammatory cycle. Giving steroids during an active viral
t of Defense Vaccine Healthcare Center. CK  creatine kinase; CRP 
rate; FU follow-up; LVEF left ventricular ejection fraction; NSAID
erase chain reaction.rtmen
tation
polymnfection could in theory cause the patient to worsen by
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Smallpox Vaccination and Myopericarditis May 5, 2004:1503–10nducing an immunosuppressed state. Thus the efficacy of
mmunosuppression in post-vaccinial myopericarditis de-
ends upon there being a post-infectious autoimmune
nflammatory process as the cause, in which active viral
nfection does not play a role.
A series of studies address the role of immunosuppression
n myocarditis unrelated to smallpox vaccination. Mason et
l. (51) conducted a randomized trial of immunosuppressive
herapy in patients with a left ventricular ejection fraction
45% and histopathologic diagnosis of myocarditis (lym-
hocytic infiltrate on cardiac biopsy) and showed no signif-
cant difference in change in ejection fraction or in mortality
etween the immunosuppressed group or the control group.
onversely, Camargo et al. (62) reported a benefit to
rednisone with azathioprine or cyclosporine, over pred-
isone alone or just conventional treatment, in children with
ilated cardiomyopathy and biopsy-proven active myocar-
itis. Likewise, Frustaci et al. (63) showed that patients with
ctive lymphocytic myocarditis, circulating cardiac autoan-
ibodies, and no viral genome in the myocardium respond
avorably (by left ventricular function evaluation) to immu-
osuppression with prednisone and azathioprine. These
odels of myocarditis not associated with vaccinia may or
ay not have relevance to the vaccinia-associated disease
resentation.
Thus far there have been only two cases reported of
ost-vaccinial myopericarditis treated with immunosup-
ressives. Murphy et al. (64) recently described a 29-year-
ld man who developed symptomatic heart failure three
eeks after smallpox vaccination. The patient was treated
ith standard heart failure medications as well as high-dose
orticosteroids. Within 10 days the patient had resolution of
eart failure, a return of normal ventricular function, and
esolution of serum inflammatory markers. A second case
ith post-immunization epicarditis, which was complicated
y a fatal alveolitis, also did not demonstrate evidence of
iral tissue infection.
Both cases, the first with endomyocardial biopsy and the
econd from autopsy examination, demonstrated a mixed
ymphocytic infiltrate with eosinophil degranulation in areas
f myocardial necrosis, suggesting an immune inflammatory
echanism of myocardial injury. These observations suggest
hat vaccinia-associated myopericarditis is due to an im-
une inflammatory response rather than a viral infection of
he myocardium or pericardium.
on-steroidal anti-inflammatory drugs (NSAIDs). The
ainstays of treatment for the symptoms of pericarditis and
yopericarditis are NSAIDs, with additional analgesics as
eeded, although there are no controlled clinical trials, and
SAIDs are not recommended in the first two weeks of
ure myocarditis. Ibuprofen may be the preferred agent, as
t has been found to be less gastrointestinally toxic than
thers in its class. In theory, any NSAID may be effective.
ecommended doses of ibuprofen vary from 300 to 800 mg
very 8 h as needed for symptom relief, and duration of
reatment may be as little as a few days or may be for weeks c65). There is one recent case report of myocarditis after
mallpox vaccination treated successfully with NSAIDs
66).
IG. Vaccinia immune globulin has been shown to be
seful in the treatment of certain non-cardiac complications
f the smallpox vaccine, to include progressive vaccinia,
czema vaccinatum, and ocular vaccinia, all of which are
inked with uncontrolled vaccinia replication. Although it is
elpful in these situations, only one publication reports its
se in myocarditis after smallpox vaccination, in a six-year-
ld boy who recovered after treatment with both VIG and
teroids (29). Given the absence of any proof of active viral
nfection in our experience with the DoD vaccinees, and the
ack of historical proof in the literature, it is more likely that
ost-vaccinial myopericarditis is a non-infectious process
hat will not benefit from the anti-viral effect of VIG, or for
hat matter any other specific antiviral therapy.
est. Recommendations for rest after acute myocarditis are
ased on animal studies showing a large increase in mortal-
ty in mice that are made to exercise strenuously after
nfection with Coxsackie virus (67–69). A study reviewing
udden cardiac death in U.S. Air Force recruits found 17 of
9 cases to be associated with strenuous exertion, and of
hese 5 were associated with myocarditis, 1 post-vaccinial
39). Patients who have myocarditis and undergo exercise
tress tests are more likely to show ectopic activity, and in
act older series have used this as a criterion for myoperi-
arditis (20). Even at rest, patients with myopericarditis
how more ectopy (19,44,70). These limited data suggest
hat avoidance of high-level exertion during the recovery
nd healing phase of myopericarditis (four to six weeks) is
dvisable.
onventional heart failure treatment. Post-vaccinial
yopericarditis that leads to left ventricular dysfunction
hould be treated no differently than other cases of cardio-
yopathy with regard to management of the heart failure.
eta-blockers such as carvedilol or long-acting metoprolol
s well as the angiotensin-converting enzyme inhibitors
ave been shown to be beneficial and should be used unless
ot tolerated by the patient. Diuretics, nitrates, and digoxin
hould be used as needed for symptom control. If needed,
ositive inotropes and left ventricular assist devices may be
mployed.
reatment summary. Historically, most cases of post-
accinial myopericarditis were self-limited and resolved
ompletely in time (1,13–25). Unfortunately, a few did not
11,13,35,38,39). Therapeutic approaches to myopericarditis
fter vaccinia immunization are based on limited data, and
here is a clear need for improved evidence regarding the
fficacy of different approaches. In the absence of other etiol-
gies and no evidence of active vaccinia systemic infection,
on-steroidal anti-inflammatory therapy in most patients fol-
owed by corticosteroids in those with a more severe clinical
resentation (reduced left ventricular function, evidence of
ongestive heart failure) appears to be a reasonable approach, in
ombination with conventional heart failure medications and
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May 5, 2004:1503–10 Smallpox Vaccination and Myopericarditisvoidance of high-level exertion. The role of VIG remains
nclear, particularly in the absence of evidence suggesting an
ctive viral infection. At the current time, the state of knowl-
dge does not support a definitive evidence-based guideline,
nd continued outcomes data collection on patients affected
ith this problem is needed.
UTURE DIRECTIONS
uture research is needed to better quantify the risk of
yopericarditis after smallpox vaccination. A prospective
rial following participants with serial ECGs and physical
xaminations, with confirmatory studies, as needed, is being
lanned. Further investigation should attempt to better
lucidate whether post-vaccinial myopericarditis is a non-
nfectious immune reaction that is uniquely responsive to
teroids. Also, more experience with diagnostic modalities is
eeded. Whether MRI, nuclear studies, laboratory evalua-
ion, or something else entirely will become the confirma-
ory test of choice needs to be explored further. Myocarditis
tself remains a poorly understood entity, and may be a final
esult of a process that can have multiple pathways (e.g.,
schemic, infectious, post-infectious, autoimmune, toxic).
inally, we need to continue to follow patients diagnosed
ith post-vaccinial myopericarditis to establish whether
ong-term sequelae exist.
UMMARY
ardiac complications of smallpox vaccination, originally
hought to be rare, have in the last 10 months of experience
roven to be more common. Chest pain or heart failure
ymptoms after smallpox vaccination should be taken seri-
usly and addressed with a diagnostic workup, treated
ppropriately, and reported to the CDC or the Vaccine
dverse Events Reporting System. Recently, the overall rate
f symptomatic myopericarditis in DoD personnel after
mallpox vaccination has approached approximately 1 in
0,000, a rate similar to that reported in some European
tudies from the 1960s. These cases have been detected via
areful monitoring of vaccinees by the DoD using clinical
creening for symptoms, and when indicated ECG, labora-
ory assay for myocardial injury, and echocardiogram. Fur-
her tests have been utilized as clinically indicated to rule out
schemic disease and other causes of cardiac inflammation.
nly two cases have been histologically confirmed, but in
either of these cases nor in serum from 32 other affected
atients has there been any evidence of vaccinia. Histology
as shown a mixed lymphocytic infiltrate with eosinophil
egranulation in areas of myocardial necrosis. These find-
ngs support a non-infectious pathogenesis of inflammation,
imilar to hypersensitivity myocarditis, which might be
specially responsive to immunosuppression, a hypothesis
hat has held true in at least one case.
Although there is limited information regarding the risk
o individuals with a history of congestive heart failure or
oronary artery disease, such individuals should be excludedrom smallpox vaccinations on the theoretical premise that
ncreased inflammation could exacerbate a chronic problem.
ikewise, there is little known on the potential additional
isk portended by a previous episode of myopericarditis.
ntil further investigation can answer this question, we
upport a conservative approach not vaccinating individuals
ith a history of myopericarditis of any etiology.
The total number affected remains relatively small given
he limited scope of smallpox vaccinations since December
002. However, in the event of more widespread vaccine
dministration, in a population that could be less healthy
han the U.S. military population, there is the potential for
housands of related myopericarditis cases. Fortunately,
ost of the recent cases, which receive ongoing review, have
ecovered promptly and completely, with follow-up assess-
ents of their symptomatology, ejection fraction, and ex-
rcise capacity. Long-term follow-up to document stability
f recovery is under way.
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